Tempest Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Tempest Therapeutics, Inc. on May 6, 2026. The report discloses non-financial corporate events, specifically the release of an updated corporate presentation and a press release regarding clinical updates presented at the ISCT 2026 Annual Meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory disclosure of corporate communications rather than financial performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing serves to disseminate new information regarding clinical progress and corporate strategy updates.
Guidance, Outlook, and Management Commentary
- Clinical Update: The Company issued a press release on May 6, 2026, detailing a clinical update presented at the ISCT 2026 Annual Meeting.
- Corporate Presentation: An updated corporate presentation dated May 6, 2026, was posted to the Company's investor relations website.
- Legal Status: The information furnished in this Item 7.01 and the attached exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference except as expressly provided.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific details on the clinical update presented at ISCT 2026.
- Access the updated corporate presentation (Exhibit 99.2) on the Company's website for strategic outlook.
- Verify the Company's status as an emerging growth company (indicated as checked in the filing).
- Confirm the trading symbol TPST on The Nasdaq Stock Market LLC.